@article{article_1748140, title={Polypharmacy and Accompanying Comorbid Conditions in Kidney Transplant Recipients: A Retrospective Study}, journal={Journal of Cukurova Anesthesia and Surgical Sciences}, volume={8}, pages={313–319}, year={2025}, author={Onan, Engin and Paydas, Saime and Balal, Mustafa and Taşkapan, Hülya and Bozacı, İlter}, keywords={Polifarmasi, Böbrek nakli, Komorbiditeler, İlaç yönetimi, İmmünsüpresif tedavi}, abstract={Background: Kidney transplantation improves survival and quality of life, yet post-transplant care frequently necessitates complex pharmacotherapy due to immunosuppressive regimens and management of comorbidities. This often results in polypharmacy, which is associated with increased risk of adverse outcomes. In this study, we aimed to evaluate the immunosuppressive and other medications used in kidney transplant recipients, as well as the accompanying comorbid conditions. Methods: In this cross-sectional, multicenter study, 342 kidney transplant recipients were stratified into two groups: low-risk (≤5 medications) and moderate-to-high risk (≥6 medications) polypharmacy. Demographic, clinical, and laboratory data were analyzed to identify predictors of polypharmacy using multivariate logistic regression. Results: Moderate-to-high polypharmacy was observed in 64.9% of patients. This group had significantly higher creatinine, blood urea nitrogen (BUN), and glucose levels, and lower eGFR and hemoglobin values (all p  < 0.05). Hypertension, diabetes, and coronary artery disease were more common in this group (p = 0.001). In multivariate analysis, hypertension (OR: 4.615), proton pump inhibitor use (OR: 5.705), and allopurinol use (OR: 10.894) were independently associated with polypharmacy, while anticoagulant use was inversely associated (OR: 0.237; all p  < 0.01). Conclusion: Polypharmacy is prevalent among our kidney transplant recipients and is associated with impaired graft function, anemia, and higher comorbidity burden. Certain medications, particularly PPIs and allopurinol, are strong predictors of polypharmacy. These findings highlight the need for individualized medication review, deprescribing strategies, and integration of pharmacogenomics into routine care to optimize outcomes in transplant recipients.}, number={3}, publisher={Merthan TUNAY}